What causes bcr abl translocation

Overview

The BCR-ABL translocation is a pivotal genetic event in the development of certain types of leukemia, most notably Chronic Myeloid Leukemia (CML). This translocation is not a disease in itself, but rather the underlying genetic cause that leads to the uncontrolled proliferation of white blood cells. Understanding this translocation is crucial for diagnosing and treating these hematological malignancies.

What is a Chromosomal Translocation?

Chromosomal translocations are a type of mutation where segments of two different chromosomes break and are exchanged. Think of chromosomes as chapters in the book of our genetic code. A translocation is like swapping pages between two different chapters, which can disrupt the normal sequence and function of genes.

The Specifics of the BCR-ABL Translocation

In the case of the BCR-ABL translocation, the abnormality occurs between chromosome 9 and chromosome 22. Specifically, a piece of chromosome 9 containing the ABL1 gene breaks off and attaches to chromosome 22. Conversely, a piece of chromosome 22 containing part of the BCR gene breaks off and attaches to chromosome 9.

This reciprocal exchange results in the formation of an abnormal chromosome 22, which is famously known as the Philadelphia chromosome (named after the city where it was first discovered). This Philadelphia chromosome also leads to the creation of a fusion gene called BCR-ABL.

The Role of the BCR-ABL Fusion Gene and Protein

The BCR-ABL fusion gene produces an abnormal protein that is a type of enzyme called a tyrosine kinase. Normally, tyrosine kinases act as switches, turning cellular growth and division on and off. However, the BCR-ABL tyrosine kinase is constitutively active, meaning it is always 'on'.

This constant activation sends continuous signals to the cell to grow and divide, even when it's not supposed to. This uncontrolled cell division leads to the overproduction of white blood cells, particularly granulocytes, which is the hallmark of CML. These abnormal cells can accumulate in the bone marrow and blood, interfering with the production of normal blood cells and eventually leading to symptoms of leukemia.

How Does the Translocation Occur?

It's important to understand that the BCR-ABL translocation is an acquired mutation. This means it is not inherited from parents; rather, it arises spontaneously in a person's bone marrow cells during their lifetime. The exact trigger for this translocation is unknown, but it's believed to be a random event that occurs during cell division. Factors like exposure to high doses of radiation have been linked to an increased risk of chromosomal abnormalities, but for most individuals, the cause remains elusive.

Significance in Leukemia Diagnosis and Treatment

The identification of the Philadelphia chromosome and the BCR-ABL translocation is a critical diagnostic marker for CML. It is present in approximately 95% of CML cases and about 20-30% of adult Acute Lymphoblastic Leukemia (ALL) cases. The presence of this translocation allows for targeted therapies.

The development of tyrosine kinase inhibitors (TKIs), such as imatinib (Gleevec), revolutionized CML treatment. These drugs specifically target the BCR-ABL protein, inhibiting its activity and controlling the leukemia. This targeted approach has dramatically improved outcomes for patients with BCR-ABL positive leukemias.

Summary

In essence, the BCR-ABL translocation is a genetic accident that creates a rogue protein driving leukemia. It's a defining characteristic of CML and a key target for modern cancer therapies, underscoring the power of understanding molecular genetics in fighting disease.